Search Results - "Laffont, Céline M."

Factors for Hematopoietic Toxicity of Carboplatin: Refining the Targeting of Carboplatin Systemic Exposure by SCHMITT, Antonin, GLADIEFF, Laurence, PINGUET, Frédéric, FLOQUET, Anne, BILLAUD, Eliane M, DURDUX, Catherine, LE GUELLEC, Chantal, MAZIERES, Julien, LAFONT, Thierry, OLLIVIER, Florent, CONCORDET, Didier, CHATELUT, Etienne, LAFFONT, Céline M, EVRARD, Alexandre, BOYER, Jean-Christophe, LANSIAUX, Amélie, BOBIN-DUBIGEON, Christine, ETIENNE-GRIMALDI, Marie-Christine, BOISDRON-CELLE, Michèle, MOUSSEAU, Mireille

“…Area under the curve (AUC) dosing is routinely carried out for carboplatin, but the chosen target AUC values remain largely empirical. This multicenter…”
Get full text

Similarity of Bisphenol A Pharmacokinetics in Rhesus Monkeys and Mice: Relevance for Human Exposure by Taylor, Julia A., vom Saal, Frederick S., Welshons, Wade V., Drury, Bertram, Rottinghaus, George, Hunt, Patricia A., Toutain, Pierre-Louis, Laffont, Céline M., VandeVoort, Catherine A.

“…Objective: Daily adult human exposure to bisphenol A (BPA) has been estimated at < 1 μg/kg, with virtually complete first-pass conjugation in the liver in…”
Get full text

Intestinal Secretion Is a Major Route for Parent Ivermectin Elimination in the Rat by LAFFONT, Celine M, TOUTAIN, Pierre-Louis, ALVINERIE, Michel, BOUSQUET-MELOU, Alain

“…The transepithelial intestinal elimination of ivermectin was studied using the intestinal closed-loop model in the rat. The common bile duct was cannulated,…”
Get full text

Comparison of intranasal naloxone and intranasal nalmefene in a translational model assessing the impact of synthetic opioid overdose on respiratory depression and cardiac arrest by Laffont, Celine M, Purohit, Prasad, Delcamp, Nash, Gonzalez-Garcia, Ignacio, Skolnick, Phil

“…Using a validated translational model that quantitatively predicts opioid-induced respiratory depression and cardiac arrest, we compared cardiac arrest events…”
Get full text

Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients by Moss, Laurence M, Algera, Marijke Hyke, Dobbins, Robert, Gray, Frank, Strafford, Stephanie, Heath, Amy, van Velzen, Monique, Heuberger, Jules A A C, Niesters, Marieke, Olofsen, Erik, Laffont, Celine M, Dahan, Albert, Groeneveld, Geert Jan

“…Opioid-induced respiratory depression driven by ligand binding to mu-opioid receptors is a leading cause of opioid-related fatalities. Buprenorphine, a partial…”
Get full text

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder by Laffont, Celine M., Ngaimisi, Eliford, Gopalakrishnan, Mathangi, Ivaturi, Vijay, Young, Malcolm, Greenwald, Mark K., Heidbreder, Christian

“…The severity of the ongoing opioid crisis, recently exacerbated by the COVID-19 pandemic, emphasizes the importance for individuals suffering from opioid use…”
Get full text

Are population pharmacokinetic and/ or pharmacodynamic models adequately evaluated? : A survey of the literature from 2002 to 2004 by BRENDEL, Karl, DARTOIS, Céline, COMETS, Emmanuelle, LEMENUEL-DIOT, Annabelle, LAVEILLE, Christian, TRANCHAND, Brigitte, GIRARD, Pascal, LAFFONT, Céline M, MENTRD, France

“…Model evaluation is an important issue in population analyses. We aimed to perform a systematic review of all population pharmacokinetic and/or pharmacodynamic…”
Get full text

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder by Greenwald, Mark K, Wiest, Katharina L, Haight, Barbara R, Laffont, Celine M, Zhao, Yue

“…BUP-XR (SUBLOCADE ) is the first buprenorphine extended-release subcutaneous injection approved in the USA for monthly treatment of moderate-to-severe opioid…”
Get full text

A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection by Sadiq, Muhammad W., Nielsen, Elisabet I., Khachman, Dalia, Conil, Jean-Marie, Georges, Bernard, Houin, Georges, Laffont, Celine M., Karlsson, Mats O., Friberg, Lena E.

“…The purpose of this study was to develop a whole-body physiologically based pharmacokinetic (WB-PBPK) model for ciprofloxacin for ICU patients, based on only…”
Get full text

Model-Based Approach to Describe G-CSF Effects in Carboplatin-Treated Cancer Patients by Pastor, Mélanie L., Laffont, Céline M., Gladieff, Laurence, Schmitt, Antonin, Chatelut, Etienne, Concordet, Didier

“…ABSTRACT Purpose Granulocyte colony-stimulating factor (G-CSF) is often used in cancer patients receiving cytotoxic drugs to prevent or reduce high grade…”
Get full text

Modeling buprenorphine reduction of fentanyl-induced respiratory depression by Olofsen, Erik, Algera, Marijke Hyke, Moss, Laurence, Dobbins, Robert L, Groeneveld, Geert J, van Velzen, Monique, Niesters, Marieke, Dahan, Albert, Laffont, Celine M

“…BACKGROUNDPotent synthetic opioids, such as fentanyl, are increasingly abused, resulting in unprecedented numbers of fatalities from respiratory depression…”
Get full text

Model-Based Approach to Early Predict Prolonged High Grade Neutropenia in Carboplatin-Treated Patients and Guide G-CSF Prophylactic Treatment by Pastor, Mélanie L., Laffont, Céline M., Gladieff, Laurence, Chatelut, Etienne, Concordet, Didier

“…Purpose Neutropenia is a major dose-limiting side effect of chemotherapy and is closely related to febrile neutropenia which mainly occurs during the first…”
Get full text

Use of Monte Carlo simulation to determine pharmacodynamic cutoffs of amoxicillin to establish a breakpoint for antimicrobial susceptibility testing in pigs by Rey, Julien F, Laffont, Céline M, Croubels, Siska, De Backer, Patrick, Zemirline, Claudine, Bousquet, Eric, Guyonnet, Jérôme, Ferran, Aude A, Bousquet-Melou, Alain, Toutain, Pierre-Louis

“…To determine pharmacodynamic cutoffs with pharmacokinetic-pharmacodynamic principles and Monte Carlo simulation (MCS) for use of amoxicillin in pigs to set…”
Get full text

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder by Dong, Ruihua, Wang, Hongyun, Li, Dandan, Lang, Liwei, Gray, Frank, Liu, Yongzhen, Laffont, Celine M., Young, Malcolm, Jiang, Ji, Liu, Zeyuan, Learned, Susan M.

“…Background Two phase I studies assessed the pharmacokinetics of buprenorphine, its metabolite norbuprenorphine, and naloxone following administration of…”
Get full text

Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations by Khachman, Dalia, Conil, Jean-Marie, Georges, Bernard, Saivin, Sylvie, Houin, Georges, Toutain, Pierre-Louis, Laffont, Celine M.

“…Objectives To explore different ciprofloxacin dosage regimens for the treatment of intensive care unit (ICU) patients with respect to clinical outcome and the…”
Get full text

Development of a Complex Parent-Metabolite Joint Population Pharmacokinetic Model by Bertrand, Julie, Laffont, Céline M., Mentré, France, Chenel, Marylore, Comets, Emmanuelle

“…This study aimed to develop a joint population pharmacokinetic model for an antipsychotic agent in development (S33138) and its active metabolite (S35424)…”
Get full text

Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm by Bertrand, Julie, Comets, Emmanuelle, Laffont, Céline M., Chenel, Marylore, Mentré, France

“…Pharmacogenetics is now widely investigated and health institutions acknowledge its place in clinical pharmacokinetics. Our objective is to assess through a…”
Get full text

A Single‐Dose Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of Monthly Extended-Release Buprenorphine at Alternative Injection Locations in Adult Participants with Opioid Use Disorder by Laffont, Celine M., Lapeyra, Olga, Mangal, Dipti, Dobbins, Robert

“…Buprenorphine extended-release monthly formulation (BUP-XR, SUBLOCADE®) is approved for treatment of moderate-to-severe opioid use disorder (OUD) following…”
Get full text

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials by Jones, Aksana K., Ngaimisi, Eliford, Gopalakrishnan, Mathangi, Young, Malcolm A., Laffont, Celine M.

“…Background BUP-XR (a.k.a. RBP-6000 or SUBLOCADE™) is an extended-release subcutaneous buprenorphine formulation for the treatment of opioid use disorder…”
Get full text

Prognosis in Equine Medical and Surgical Colic by Van der Linden, Marianne A, Laffont, Celine M, Van Oldruitenborgh-Oosterbaan, Sloet

“…A retrospective study was performed on 649 horses admitted to the Clinic of Equine Internal Medicine (Utrecht University) for gastrointestinal colic. The aim…”
Get full text